A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors.

Trial Profile

A Phase 1 Study of AV-299 (Formerly SCH 900105) Administered by IV Infusion as Monotherapy in Advanced Solid Tumors, Lymphomas, or Multiple Myeloma or in Combination With Erlotinib in Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2014

At a glance

  • Drugs Ficlatuzumab (Primary) ; Erlotinib
  • Indications Hodgkin's disease; Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 23 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 19 Mar 2013 Planned end date changed from 1 Mar 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 11 Apr 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top